Zelira Therapeutics Ltd has released a press release.
December 2019 Quarterly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Story so far
Earlier from Zelira Therapeutics
- Zelira to Collaborate with the Parkinsons Foundation
- Zelira Therapeutics expands HOPE distribution in the U.S.A
- Ilera Therapeutics Merger Completed and Board Changes
- Agreement with Health House to Distribute Zelda Products
- Formulations to be supplied as part of CARE NSW trial
Later from Zelira Therapeutics
- Zelira Successfully Completes Capital Raising of $4.6M
- Zelira Meets Primary Endpoints for Insomnia Trial
- Phase 1 Opioid Reduction Clinical Trial Fully Enrolled
- Appendix 4D & FY20 Interim Financial Report
- Insomnia Trial Meets Primary and Secondary Endpoints
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics